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ment of chronic pancreatitis and pancreatic cancer through 
interaction with other genetic and environmental factors. 
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 Introduction 
 Chronic pancreatitis and pancreatic cancer are dis-
eases with complex and insufficiently explained etiology 
and pathogenesis. The origin of pancreatic disease in-
volves numerous environmental and genetic factors and 
the role of genetic factors has not been clearly defined so 
far. Several epidemiological studies have shown that in-
creasing age, male gender, fat intake and smoking repre-
sent risk factors for pancreatic cancer, while alcohol con-
sumption is the main etiological factor for the occurrence 
of chronic pancreatitis  [1–9] .
 Angiotensin-converting enzyme (ACE) is a key en-
zyme of the renin-angiotensin system, which is an en-
zyme circulatory cascade system and plays a primary role 
in the regulation of blood pressure and serum electrolytes 
homeostasis  [10, 11] . ACE converts inactive pro-hormone 
angiotensin I to the active peptide hormone and potent 
vasoconstrictor angiotensin II. Recent studies have indi-
cated the existence of a local renin-angiotensin system of 
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 Abstract 
 The purpose of this study was to determine the frequency of 
angiotensin-converting enzyme (ACE) gene insertion/dele-
tion (I/D) polymorphism and to investigate its role as a po-
tential risk factor in patients with chronic pancreatitis and 
pancreatic cancer. Deletion polymorphism of the 287-bp 
fragment of intron 16 of the ACE gene results in higher levels 
of circulating enzyme and therefore may represent a risk fac-
tor for disease development. The study included 55 patients 
with chronic pancreatitis, 45 patients with pancreatic cancer 
and 128 healthy subjects. The presence of I and D variants in 
the ACE gene was analyzed by a polymerase chain reaction 
(PCR) method. Distribution of ACE ID genotypes was ana-
lyzed by means of logistic regression. When chronic pancre-
atitis and pancreatic cancer groups were compared in the 
univariate analysis, the following factors were identified as 
statistically significant predictors of pancreatic disease: age, 
gender, smoking, fat intake, ACE II genotype and ACE DD 
genotype. However, in the multivariate analysis, only age, 
gender and smoking were singled out as predictors for the 
occurrence of pancreatic disease. Our findings indicate that 
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the endocrine and exocrine pancreas. This system is es-
sential for maintaining pancreatic homeostasis as it is in-
volved in the processes of cell proliferation, differentia-
tion, inflammation, apoptosis and fibrosis  [12] . Thus, the 
ACE gene may have a role in the occurrence of chronic 
pancreatitis and pancreatic cancer.
 The ACE gene insertion/deletion (I/D) polymorphism 
was first detected in 1990. Deletion polymorphism of the 
287-bp fragment of intron 16 of the ACE gene results in 
higher levels of circulating enzyme  [13] . It has been shown 
that the ACE deletion (DD) genotype results in a 1.3-fold 
increased risk of myocardial infarction  [14] .
 Recent studies on experimental animals have revealed 
the ACE effect on pancreatic fibrogenesis  [15] . It has also 
been proven that ACE inhibitors reduce the levels of in-
flammation and pancreatic fibrosis in rats  [16] . Thus it 
has been shown that the renin-ACE-angiotensin system 
is directly involved in the process of inducing pancreatic 
inflammation and developing chronic pancreatitis. Re-
cent studies have also revealed increased expression of 
the ACE gene in pancreatic cancer  [17] . The role of the 
ACE-angiotensinogen system in the pathogenesis of pan-
creatic cancer is reflected in its involvement in the pro-
cesses of cell growth, metastasis and angiogenesis  [18, 19] . 
However, further studies are needed to examine the fre-
quency of ACE gene polymorphism in and its contribu-
tion to the development of pancreatic diseases.
 Epidemiologic studies involving hypertensive patients 
have suggested that blocking angiotensin II may decrease 
cancer risk  [20, 21] . Angiotensin II has been shown to in-
crease vascular endothelial growth factor (VEGF) pro-
duction in cancer  [22] . Pancreatic cancer expresses a high 
level of VEGF, a crucial component of angiogenesis in 
pancreatic cancer  [23] . ACE inhibitors are widely used in 
clinical practice and may thus represent a potential novel 
and promising strategy for controlling angiogenesis and 
prevention of metastasis in patients with pancreatic can-
cer.
 The purpose of this study was to determine the fre-
quency of the ACE gene I/D polymorphism and to inves-
tigate its role as a potential risk factor in patients with 
chronic pancreatitis and pancreatic cancer.
 Patients and Methods  
 Patients 
 The study included 55 patients with chronic pancreatitis, 45 pa-
tients with pancreatic cancer and 128 healthy subjects in the control 
group. The study was carried out at the Gastroenterology and Hep-
atology Clinic and the First Surgical Clinic, while genetic testing 
was performed in the Laboratory for Molecular Biology at the In-
stitute of Molecular Genetics and Genetic Engineering in Belgrade.
 The following demographic data were analyzed for all pa-
tients: age, gender, information regarding animal fat intake, 
smoking and alcohol consumption. The subjects who smoked 
more than 20 cigarettes a day were defined as heavy smokers and 
the subjects who consumed more than 60 g of alcohol per day were 
defined as heavy drinkers. Information about fat intake was ob-
tained by way of a questionnaire which was filled in by each sub-
ject. The questionnaire included questions about how often the 
subjects used pork, lard, fatty cheeses and eggs in their daily diet.
 Chronic pancreatitis was diagnosed based on clinical and lab-
oratory data about the presence of exocrine and endocrine pan-
creatic insufficiency, and the results of morphological tests – cal-
cification of the pancreas diagnosed by abdominal ultrasound 
examination and abdominal CT or NMR scans; morphological 
changes of the pancreatic canalicular system, diagnosed by endo-
scopic retrograde cholangiopancreatography (ERCP); morpho-
logical changes of pancreas, diagnosed by endoscopic ultrasound.
 The diagnosis of pancreatic adenocarcinoma was established 
using clinical data (pain, obstructive icterus and weight loss), lab-
oratory test results (value of tumor marker CA19-9) and results of 
different diagnostic procedures (abdominal ultrasonography, ab-
dominal CT or NMR scans, pancreatic endoscopic ultrasonogra-
phy). Pathohistological tests conducted during the surgical pro-
cedures confirmed the diagnosis in all patients with pancreatic 
adenocarcinoma.
 Genotyping 
 The genotyping for ACE I/D polymorphism was performed on 
the DNA extracted from whole blood samples by QIAamp DNA 
Blood Mini Kit (Qiagen). The presence of I and D variants in the 
ACE gene was analyzed by a polymerase chain reaction (PCR) 
method using oligonucleotide primers flanking the respective 
fragment of the intron 16 of the human ACE gene. The PCR prod-
ucts were separated on 2% agarose gels stained with ethidium 
bromide. The amplification of the 490-bp-long fragment indi-
cates presence of the I allele, while the amplification of the 190-bp-
long fragment indicates presence of the D allele  [24] .
 Statistical Analysis 
 Descriptive statistics were performed with percentages for 
qualitative data, and with mean and SD for quantitative data. Cat-
egorical data were compared using Pearson’s   2 test. Continuous 
variables were compared with the use of one-way ANOVA. Data 
were analyzed by logistic regression. The ORs evaluated by the 
logistic regression together with their 95% CIs were also reported. 
All reported p values were two-sided; differences were considered 
significant when p was  ! 0.05.
 Results  
 The study included 45 patients with pancreatic cancer 
and 55 patients with chronic pancreatitis, while the con-
trol group included 128 healthy subjects. Male gender was 
significantly more represented in all 3 groups, with the 
highest frequency of male subjects noted in the chronic 
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pancreatitis group ( table 1 ). Female subjects were signifi-
cantly more represented in the pancreatic cancer group 
in comparison to the chronic pancreatitis group. Subjects 
with pancreatic cancer were significantly the oldest, 
while the control group subjects were the youngest. Com-
pared with pancreatic cancer patients, a higher number 
of chronic pancreatitis patients consumed alcohol, al-
though the difference was not statistically significant. 
The highest frequency of subjects characterized by fat in-
take was observed in the pancreatic cancer group.
 The analysis of the distribution of ACE genotypes
has revealed statistically significant difference between 
 pancreatic cancer and chronic pancreatitis groups and 
between pancreatic cancer and healthy subjects groups, 
while the difference between chronic pancreatitis and 
healthy subjects groups was not statistically significant. 
Each ACE genotype was analyzed as a risk factor for 
 pancreatic cancer and chronic pancreatitis by means of 
logistic regression analysis. When pancreatic cancer and 
chronic pancreatitis groups were compared, in the uni-
variate analysis the following factors were identified as 
statistically significant: age, gender, smoking, fat intake, 
ACE II genotype and ACE DD genotype. However, in the 
multivariate analysis only age, gender and smoking were 
singled out as predictors for the occurrence of a pancre-
atic disease ( table 2 ). Through analysis of single predic-
tors it was observed that females have 4 times higher risk 
of pancreatic cancer occurrence, that each year of life in-
creases risk of pancreatic cancer for 6% and that smokers 
are at 3 times higher risk of pancreatic cancer occurrence.
 Discussion 
 The origin of pancreatic disease involves many envi-
ronmental and genetic factors, and their roles have not 
yet been clearly defined. This study is the first to investi-
gate the frequency of ACE I/D polymorphism in patients 
with pancreatic cancer and one of a few analyzing this 
polymorphism in chronic pancreatitis patients.
 The only confirmed etiological factors in pancreatic 
cancer and chronic pancreatitis development are smok-
ing and alcohol consumption, respectively. The findings 
of this study are in correlation with previous findings 
which indicate that age, gender, smoking, alcohol and fat 
intake increase risk of pancreatic disease  [25–31] .
 In this study, there were more men than women in the 
groups of patients with pancreatic cancer and chronic 
pancreatitis, but also in the control group. In patients 
with pancreatic cancer, the men:women ratio was 1.5: 1, 
which indicates that the number of women who develop 
pancreatic cancer is increasing  [25] .
 While most studies report average age of over 65 years 
in patients with pancreatic cancer, in this study pancre-
atic cancer patients were 60.9 years old. The average age 
of patients with chronic pancreatitis was 53.1 years, which 
correlates with findings of other studies  [26] .
 Smoking is considered to be the only proven risk factor 
for pancreatic cancer  [27, 28] . In this study, distribution 
of smokers differed significantly between the groups. 
They were more frequent in pancreatic cancer patients 
(64.4%) than in chronic pancreatitis patients (42.6%).
 The only confirmed etiological factor in chronic pan-
creatitis development is alcohol consumption  [9] . In this 
study, the vast majority of chronic pancreatitis patients 
(73.3%) were found to be alcohol consumers, which is in 
correlation with findings of other studies  [9] . Alcohol 
consumption was more frequent in patients with chronic 
Table 1.  Characteristics of the analyzed groups
Parameters G roups p value
pancreatic 
cancer
chronic 
pancreatitis 
healthy 
subjects
Total number 45 55 128
Gender (M/F) 27/18 46/9 93/35 0.030*, a
0.008*, b
0.113c
0.111d
Mean age
8 SD 60.9810.6 53.1812.5 40.1810.5
0.000*, a
0.001*, b
0.000*, c
0.000*, d
Smoking, n 29 (64.4) 23 (42.6) – 0.030*, b
Alcohol, n 25 (55.6) 40 (72.7) – 0.073b
Fatty food
intake, n 31 (68.9) 27 (49.1) – 0.046*, b
ACE, n
ID
DD
II
17 (37.8)
4 (8.9)
24 (53.3)
22 (40.0)
18 (32.7)
15 (27.3)
72 (56.3)
26 (20.3)
30 (23.4)
0.000*, a
0.005*, b
0.001*, c
0.097d
Fig ures in parentheses are percentages.
* Statistically significant: a between all 3 groups; b between 
pancreatic cancer and chronic pancreatitis; c between pancreatic 
cancer and healthy subjects; d between chronic pancreatitis and 
healthy subjects.
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pancreatitis than in patients with pancreatic cancer, but 
the difference was not statistically significant.
 The highest frequency of subjects who consumed fatty 
food was observed in pancreatic cancer patients and this 
study indicated that fat intake represents a risk factor for 
pancreatic cancer, which is in correlation with results of 
other studies  [29–31] .
 Results of this study indicate association between ACE 
I/D polymorphism and pancreatic diseases. The ID ge-
notype was most frequent in healthy individuals group, 
and statistical analysis indicates that carriers of the ID 
genotype are at the lowest risk of developing analyzed 
pancreatic diseases.
 The DD genotype of the ACE I/D polymorphism
was significantly more frequent in chronic pancreatitis 
(32.7%) than in pancreatic cancer (8.9%), which indicates 
that in carriers of the DD genotype the risk of chronic pan-
creatitis is higher than the risk of pancreatic cancer. The 
ACE II genotype was associated with pancreatic cancer, 
while the ACE DD genotype was associated with chronic 
pancreatitis. Results of other studies have not indicated a 
correlation between ACE I/D polymorphism and patho-
genesis and progression of chronic pancreatitis. Oruc et al. 
 [32] have found similar frequencies of the ACE DD geno-
type in groups of patients with sporadic and familial pan-
creatitis and healthy individuals. Also, Hucl et al.  [33]  have 
not found any significant differences in ACE DD genotype 
frequency in acute and chronic pancreatitis in comparison 
to the control group. Similar findings were reported by 
Indian authors who investigated the role of the ACE I/D 
polymorphism in tropical calcifying pancreatitis  [34] . The 
frequency of the ACE II genotype was highest in the group 
of patients with pancreatic cancer and subjects with this 
genotype were found to be at higher risk of developing 
pancreatic cancer. However, the ACE DD gen otype was 
identified as risk factor only in univariate  regression anal-
ysis, but not in multivariate regression analysis. Such find-
ing indicates that the influence of the ACE genotype on 
pancreatic disease development is not independent and 
may be associated with other risk factors.
 Having in mind the importance of the role of ACE in 
pancreatic diseases, numerous studies have researched 
the potential roles of ACE inhibitors as protective factors 
in angiogenesis control in pancreatic cancer. Thus, the 
Arafat et al.  [17] study has shown that blocking endoge-
nous angiotensin II by captopril or losartan significantly 
suppressed cell proliferation in human pancreatic cancer. 
The study by German authors from 2010 proved enalapril 
and aspirin to be effective chemopreventive agents by de-
laying the progression of pancreatic intraepithelial neo-
plasia and cancer formation in a genetically engineered 
mouse model of pancreatic cancer  [35] .
 Based on the findings of the aforesaid studies and the 
results of this study, we propose further research attempts 
to investigate possibility of prophylactic admission of 
small doses of ACE inhibitors in older female patients 
with chronic pancreatitis who are smokers and carriers 
of the ACE II genotype, for the purpose of pancreatic can-
cer prevention  [17, 35] . 
 Logistic regression analysis has identified the ACE 
genotype as a statistically significant predictor of pancre-
atic disease in the univariate analysis. However, it has not 
singled it out as predictor for the occurrence of pancre-
atic disease in the multivariate analysis.  This finding can 
be explained by the fact that chronic pancreatitis and 
pancreatic cancer are multifactorial diseases with com-
Table 2.  Logistic regression analysis for pancreatic cancer and chronic pancreatitis
Parameters U nivariate Multivariate
OR (95% CI) p value OR (95% CI) p value
Gender 0.293 (0.116–0.744) 0.010* 0.250 (0.078–0.806) 0.020*
Age 0.941 (0.905–0.979) 0.002* 0.940 (0.899–0.984) 0.007*
Smoking 2.443 (1.082–5.517) 0.032* 3.154 (1.109–8.972) 0.031*
Alcohol 0.469 (0.203–1.081) 0.075 – –
Fatty food intake 2.296 (1.008–5.231) 0.048* 1.310 (0.473–3.628) 0.604
ACE: ID vs. DD+II 0.911 (0.406–2.045) 0.821 – –
ACE: II vs. ID+DD 3.048 (1.324–7.015) 0.009* 1.666 (0.598–4.641) 0.329
ACE: DD vs. II+ID 0.201 (0.062–0.647) 0.007* 0.358 (0.084–1.526) 0.165
*  Statistically significant.
 Lukic et al. Dig Surg 2011;28:258–262262
plex etiology, for which interplay of various genetic and 
non-genetic factors is characteristic. It is possible that the 
ACE I/D polymorphism plays a role in the development 
of chronic pancreatitis and pancreatic cancer through in-
teraction with other genetic and environmental factors.
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